Cargando…

Sugammadex: clinical development and practical use

Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs-Buder, Thomas, Meistelman, Claude, Raft, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Anesthesiologists 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888841/
https://www.ncbi.nlm.nih.gov/pubmed/24427454
http://dx.doi.org/10.4097/kjae.2013.65.6.495
_version_ 1782299116252954624
author Fuchs-Buder, Thomas
Meistelman, Claude
Raft, Julien
author_facet Fuchs-Buder, Thomas
Meistelman, Claude
Raft, Julien
author_sort Fuchs-Buder, Thomas
collection PubMed
description Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine.
format Online
Article
Text
id pubmed-3888841
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Korean Society of Anesthesiologists
record_format MEDLINE/PubMed
spelling pubmed-38888412014-01-14 Sugammadex: clinical development and practical use Fuchs-Buder, Thomas Meistelman, Claude Raft, Julien Korean J Anesthesiol Review Article Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine. The Korean Society of Anesthesiologists 2013-12 2013-12-26 /pmc/articles/PMC3888841/ /pubmed/24427454 http://dx.doi.org/10.4097/kjae.2013.65.6.495 Text en Copyright © the Korean Society of Anesthesiologists, 2013 http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Fuchs-Buder, Thomas
Meistelman, Claude
Raft, Julien
Sugammadex: clinical development and practical use
title Sugammadex: clinical development and practical use
title_full Sugammadex: clinical development and practical use
title_fullStr Sugammadex: clinical development and practical use
title_full_unstemmed Sugammadex: clinical development and practical use
title_short Sugammadex: clinical development and practical use
title_sort sugammadex: clinical development and practical use
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888841/
https://www.ncbi.nlm.nih.gov/pubmed/24427454
http://dx.doi.org/10.4097/kjae.2013.65.6.495
work_keys_str_mv AT fuchsbuderthomas sugammadexclinicaldevelopmentandpracticaluse
AT meistelmanclaude sugammadexclinicaldevelopmentandpracticaluse
AT raftjulien sugammadexclinicaldevelopmentandpracticaluse